NASDAQ:ARWR

Arrowhead Pharmaceuticals Stock Forecast, Price & News

$67.65
-0.33 (-0.49 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.23
Now: $67.65
$69.47
50-Day Range
$61.35
MA: $68.81
$83.78
52-Week Range
$30.83
Now: $67.65
$92.60
Volume636,217 shs
Average Volume810,714 shs
Market Capitalization$7.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Employees232
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$87.99 million
Book Value$4.51 per share

Profitability

Net Income$-84,550,000.00

Miscellaneous

Market Cap$7.02 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.1%
March 31, 2021 |  americanbankingnews.com
Accredited Virtual Event Preview- Corning, Cookware Covid
February 26, 2021 |  finance.yahoo.com
ARWR: Multiple Data Readouts in 2021…
February 9, 2021 |  finance.yahoo.com
ARWR Jan 2021 65.000 call
December 31, 2020 |  uk.finance.yahoo.com
ARWR Jan 2021 25.000 put
December 31, 2020 |  uk.finance.yahoo.com
ARWR Feb 2021 105.000 call
December 31, 2020 |  uk.finance.yahoo.com
ARWR Jan 2023 30.000 put
December 31, 2020 |  uk.finance.yahoo.com
ARWR Jun 2021 80.000 put
December 30, 2020 |  uk.finance.yahoo.com
ARROWHEAD PHARMAC. DL-,01 (HDP1.DU)
December 28, 2020 |  ca.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

498th out of 2,024 stocks

Pharmaceutical Preparations Industry

240th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$67.65
-0.33 (-0.49 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

Is Arrowhead Pharmaceuticals a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Arrowhead Pharmaceuticals?

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its quarterly earnings results on Wednesday, February, 3rd. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.00 by $1.20. The biotechnology company earned $21.30 million during the quarter, compared to analyst estimates of $157.48 million. Arrowhead Pharmaceuticals had a negative net margin of 96.09% and a negative trailing twelve-month return on equity of 17.37%.
View Arrowhead Pharmaceuticals' earnings history
.

How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARWR stock has increased by 136.9% and is now trading at $67.65.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARWR?

12 analysts have issued 1 year target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $34.00 to $110.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $85.31 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 52, Pay $1.61M)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 55, Pay $690.3k)
  • Dr. Bruce D. Given, Advisor (Age 67, Pay $486.31k)
  • Dr. Javier San Martin, Chief Medical Officer (Age 56, Pay $673.57k)
  • Mr. James Hassard, Chief Commercial Officer (Age 54, Pay $488.3k)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson, Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone, VP of Investor Relations
  • Mr. Patrick O'Brien, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 57)
  • Mr. Howard Lovy, Director of Communications

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Retirement Systems of Alabama (0.26%), Calamos Advisors LLC (0.03%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.02%), Pacer Advisors Inc. (0.01%) and Vanguard Capital Wealth Advisors (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Vanguard Capital Wealth Advisors, Pacer Advisors Inc., and State of Alaska Department of Revenue. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien, and William D Waddill.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was purchased by a variety of institutional investors in the last quarter, including First Citizens Bank & Trust Co., Retirement Systems of Alabama, Louisiana State Employees Retirement System, and Fulton Bank N.A..
View insider buying and selling activity for Arrowhead Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $67.65.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals has a market capitalization of $7.02 billion and generates $87.99 million in revenue each year. The biotechnology company earns $-84,550,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 232 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Where are Arrowhead Pharmaceuticals' headquarters?

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.